Breast Cancer
Conditions
Interventions
Three peputides restricted to HLA-A*2402(1.0mg for each)are administered 12 times once a week.
Sponsors
Department of Breast and Endocrine Surgery, Juntendo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Advanced breast cancer which is refractory to any chemotherapy. 2.Age between 20 to 85 3.ECOG performance status 0-2 4.WBC > 3000/mm3 Platelet > 75000/mm3 Hemoglobon > 9.0g/dL Serum creatinine <2.0mg/dL Asparate transaminase > 120 IU/L Alanine transaminase > 120 IU/L Total bilirubin < 2.5mg/dL 5.More than 4 weeks later after treatment(chemotherapy/radiotherapy etc) 6.Life expectancy > 3 manths 7.HLA-A*2402 8.Have a lesion which can be measured by CT/MRI 9.Able and willing to give valid written informed cansent
Exclusion criteria
Exclusion criteria: 1.No uncontrollable infections 2.No curative traumatic wound 3.No uncontrollable ulcera 4.No abnormal coagulation 5.Concurrent treatment with acetylsalicylic acid and/or NSAIDs 6.No thrombosis 7.No severe complications (heart failure etc) 8.No other malignancy requiring treatment 9.Concurrent treatment with steroids or immunosuppressing agent 10.No Psychosis 11.Pregnancy/Breast feeding 12.Decision of unsuitableness by principal investigator or physician in change
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of safety and adverse effect of vaccination therapy | — |
Countries
Japan
Outcome results
None listed